ScreenerHero

OVIDOvid Therapeutics Inc.

NAS · US · Healthcare · Biotechnology · ovidrx.com
2.800USD-4.44%Mkt Cap: 546.83M $P/E: —

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The co…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap546.83M $
Enterprise Value430.61M $
Revenue (TTM)1.58M $
Gross Profit1.58M $
Net Income (TTM)-17.41M $
Revenue/Share0.0130 USD
Last Price2.800 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees23
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS6904691010
Valuation
P/E (Trailing)—
P/E (Forward)-6.95
PEG—
EV/EBITDA-7.43
EV/Revenue272.02
P/S338.04
P/B2.41
EPS (TTM)-0.20
EPS (Forward)-0.39
52W Range
0.840087% of range3.105
52W High3.105 USD
52W Low0.8400 USD
Profitability
Gross Margin100.00%
Oper. Margin-2100.68%
EBITDA Margin0.00%
Profit Margin-240.13%
ROE-13.33%
ROA-11.54%
Growth
Revenue Growth-88.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-38.33M $
CapEx (TTM)—
FCF Margin-2092.31%
FCF Yield-6.06%
Net Debt-104.50M $
Net Debt/EBITDA1.80
Balance Sheet
Debt/Equity0.10
Current Ratio12.39
Quick Ratio11.74
Book Value/Sh1.136 USD
Cash/Share0.6000 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)5.693 USD
Upside (mean)+103.3%
Target Range4.000 USD – 9.000 USD
$4.000+103.3% to mean$9.000
# Analysts9
Ownership
Shares Out.195.30M
Float163.39M
Insiders6.72%
Institutions80.33%
Short Interest
Short Ratio12.6d
Short % Float13.26%
Short % Out.11.50%
Shares Short21.46M
Short (prev mo.)22.00M
Technical
SMA 502.509 (+11.6%)
SMA 2002.114 (+32.4%)
Beta0.23
S&P 52W Chg18.16%
Avg Vol (30d)1.50M
Avg Vol (10d)1.52M
Technical Indicators
RSI (14)60.4
MACD0.1062
MACD Signal0.0650
MACD Hist.+0.0412
BB Upper2.993 USD
BB Middle2.558 USD
BB Lower2.123 USD
BB Width34.01%
ATR (14)0.1543 USD
Vol Ratio (20d)0.85x